Physician profile

Sadia Mobeen

Brooklyn, NY

NPI 1679005276

$375.25

in general payments reported to CMS, 2019-2025

7 companies · $111 in 2025

The $111 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$316.87

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mayne Pharma Commercial LLC $79.22 2023-2024
Evofem Biosciences, INC. $75.02 2022-2024 Phexxi
Biogen, INC. $72.54 2025 Zurzuvae
Organon LLC $50.76 2023-2024 Nexplanon
Abbvie INC. $42.55 2022-2023
Exeltis, USA INC. $38.88 2025 Slynd
Merck Sharp & Dohme LLC $16.28 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sadia Mobeen

$375.25

in general payments reported 2019-2025

Years
2022-2025
Top company
Mayne Pharma Commercial LLC
Context
The $111 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/11419437/sadia-mobeen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.